What is McKesson's oncology & multispecialty — other?

McKesson (MCK) reported oncology & multispecialty — other of $0 in Q1 2026.

How has McKesson's oncology & multispecialty — other changed year-over-year?

McKesson's oncology & multispecialty — other increased by 100.0% year-over-year, from -$250K to $0.

What does oncology & multispecialty — other mean?

Residual items within the oncology and multispecialty segment that do not fit into defined categories like revenue, depreciation, or restructuring. This captures miscellaneous operational variances or minor segment-specific expenses.

McKesson MCK Oncology & Multispecialty — Other

Other segment segments

North American Pharmaceutical

-$1M—

Medical-Surgical Solutions

$500K—

Prescription Technology Solutions

$0—

Similar metrics at other companies

CNASpecialty — Other expenses

$12M-20.0%

MDTMedical Surgical — Other segment items

$5M+25.0%

AFLCancer — Other

$0—

AMRXSpecialty — Other

$905K-27.5%

SNDXBiopharmaceutical Cancer Therapeutics — Other Operating Income Expense Net

$186K-15.8%

WELLOutpatient Medical — Other segment expenses

$3.2M-55.8%

Other financials

Income statement

See full

Revenue$96.3B+6.0%

Gross profit$4.0B+11.1%

Operating income$2.2B+35.1%

Net income$1.7B+33.5%

EPS (diluted)$13.65+37.6%

Balance sheet

See full

Cash & equivalents$4.0B-33.3%

Total debt$2.3B-74.2%

Total equity-$2.2B-4.7%

Total assets$82.3B+9.6%

Cash flow

See full

Operating cash flow$3.4B-55.8%

CapEx$111.0M-34.3%

Free cash flow$3.3B-56.3%

Valuation

See full

Market cap$101.33B+17.0%

Enterprise value$99.63B+4.7%

P/E21.3×-6.1×

P/S0.3×0.0×

Profitability

See full

Gross margin3.6%-0.1pp

Operating margin1.5%+0.3pp

Net margin1.2%+0.3pp

FCF margin1.4%-0.1pp

Returns & leverage

See full

Return on equity36%—

Debt / equity2×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringReserveTranslationAndOtherAdjustment.

The official record: McKesson’s 10-K, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's oncology & multispecialty — other.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is McKesson's oncology & multispecialty — other?: McKesson (MCK) reported oncology & multispecialty — other of $0 in Q1 2026.
How has McKesson's oncology & multispecialty — other changed year-over-year?: McKesson's oncology & multispecialty — other increased by 100.0% year-over-year, from -$250K to $0.
What does oncology & multispecialty — other mean?: Residual items within the oncology and multispecialty segment that do not fit into defined categories like revenue, depreciation, or restructuring. This captures miscellaneous operational variances or minor segment-specific expenses.